Shares of UCB SA (OTCMKTS:UCBJF - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation.
Several analysts have recently commented on the company. The Goldman Sachs Group reissued a "buy" rating on shares of UCB in a report on Monday, February 16th. Stephens reissued an "overweight" rating on shares of UCB in a report on Thursday, January 15th. Finally, Wolfe Research assumed coverage on UCB in a report on Monday, February 23rd. They issued an "outperform" rating for the company.
Read Our Latest Stock Analysis on UCBJF
UCB Price Performance
UCBJF opened at $280.85 on Friday. UCB has a 52 week low of $168.65 and a 52 week high of $345.39. The business has a 50 day moving average price of $299.95 and a two-hundred day moving average price of $295.42. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
(
Get Free Report)
UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB's work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.
Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UCB, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.
While UCB currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
